ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of COVID-19 in Solid Organ Transplant Recipients in Canada 2020-2021: A Prospective, Multicenter Cohort Study

V. G. Hall1, G. Alahmadi2, J. T. Solera2, T. Marinelli2, H. Cardinal3, G. Prasad4, S. A. De Serres5, D. Isaac6, R. Mainra7, C. Lamarche8, R. Sapir-Pichhadze9, S. Gilmour10, A. Humar2, D. Kumar2

1University Health Network/Toronto General Hospital, Toronto, ON, Canada, 2UHN, Toronto, ON, Canada, 3UMontreal, Montreal, QC, Canada, 4StMH, Toronto, ON, Canada, 5Laval U, Quebec, QC, Canada, 6UCalgary, Calgary, AB, Canada, 7USaskatchewan, Saskatoon, SK, Canada, 8HMR, Montreal, QC, Canada, 9McGill U, Montreal, QC, Canada, 10SCH, Edmonton, AB, Canada

Meeting: 2022 American Transplant Congress

Abstract number: 698

Keywords: COVID-19, Infection, Multicenter studies, Vaccination

Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)

Session Information

Session Name: All Infections (Excluding Kidney & Viral Hepatitis) I

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: To understand the outcomes and changes in disease severity of COVID-19 in Solid Organ Transplant (SOT) recipients over time in the context of therapeutic advances.

*Methods: We performed a multicenter, prospective cohort study of all SOT recipients diagnosed with COVID-19, across 9 transplant programs in Canada, from March 2020-November 2021. Baseline characteristics, demographics, treatment and disease severity outcomes were collected. The primary outcome was need for supplemental oxygen. Factors associated with the primary outcome and changes in outcomes over time were analyzed. Pandemic time periods were divided into four time frames coinciding with 4 waves in North America.

*Results: We enrolled 509 SOT recipients with confirmed COVID-19 during the study period. The risk factors associated with oxygen requirement are outlined in Table 1. Severe disease and mortality were greatest in lung transplant recipients compared to other organ types (15/48 (31.3%) lung deaths vs 63/461(13.7%) nonlung organs, (p=0.001). There was no influence of 2-dose vaccination and 3 patients were infected after 3-dose vaccine. Disease with alpha or delta variant was not associated with increased oxygen requirement. In a subgroup analysis of participants requiring oxygen (n=190), remdesivir was associated with less death (p=0.035). Over the pandemic period (Figure 1), there were no significant changes in the proportion of patients requiring oxygen, ICU admission, ventilatory support or death.

Table 1. Baseline characteristics of the cohort as per oxygen requirement.
Characteristic, n (%) No oxygen requirement, n = 319 Oxygen requirement, n = 190 p value
Age (years), median, IQR 55.0 (42.8 – 63.0) 62.1 (52.0 – 69.0) <0.001
Number of comorbidities, median, IQR 2 (1-3) 3 (2-3) <0.001
Lung transplant, n, % 19 (5.96) 29 (15.3) <0.001
Liver transplant, n, % 64 (20.1) 15 (7.89) <0.001
Prednisone, n, % 237 (74.3) 174 (91.6) <0.001
Mycophenolate mofetil/ mycophenolate sodium, n, % 218 (68.3) 152 (80) 0.004
Lymphocyte count at diagnosis (103 cells/μL), median (IQR) 0.975 (0.60 – 1.5) 0.635 (0.40 – 1.0) <0.001

Figure 1. Disease severity outcomes & change over time from Jan, 2020 – Nov, 2021.

*Conclusions: COVID-19 is especially severe in lung transplant recipients and immunosuppression plays a significant role. The outcomes associated with COVID-19 in SOT have not appreciably changed over time despite the emergence of novel variants and changes in therapeutic regimens.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hall VG, Alahmadi G, Solera JT, Marinelli T, Cardinal H, Prasad G, Serres SADe, Isaac D, Mainra R, Lamarche C, Sapir-Pichhadze R, Gilmour S, Humar A, Kumar D. Outcomes of COVID-19 in Solid Organ Transplant Recipients in Canada 2020-2021: A Prospective, Multicenter Cohort Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-covid-19-in-solid-organ-transplant-recipients-in-canada-2020-2021-a-prospective-multicenter-cohort-study/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences